Drug intelligence / Profile preview

EDI-L214

Development stage: Preclinical
Lead developer: Empire Discovery Institute
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral

Overview

EDI-L214 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate developed by the Empire Discovery Institute (EDI) for the treatment of obesity. The drug is designed to target and modulate the adipose lipolysis pathway, which regulates the breakdown of stored fats in adipose tissue. By utilizing siRNA technology, EDI-L214 aims to silence specific gene expression within this pathway to improve metabolic health and reduce adiposity. As of 2024, the asset has been out-licensed by EDI and remains in the preclinical phase of development.

Beyond the preview

Go deeper on EDI-L214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDI-L214.